ABPI Final Medical Signatory  •  GMC Registered Physician  •  MBA (LBS)  •  FFPM

The UK's Leading
ABPI Compliance Expert

I help pharmaceutical teams get materials approved faster — with fewer review cycles, clearer rationale, and zero PMCPA surprises.

26+
Years in Pharma
1,900+
PMCPA Cases Analysed
6
Specialist Services
13
AI Advisors Available
📥
Free: 3 ABPI Compliance Guides built from 1,900+ real PMCPA case rulings
Get Instant Access
Free 2024 ABPI Code Cheat Sheet — Key rules & thresholds on one page
View now →
🅾 Free Assessment

Test your ABPI Code knowledge — 9 free quizzes

72 real PMCPA scenarios across 9 modules — from Basic Principles to Sales Representatives. AI-powered feedback after every answer.

✓  9 quizzes ✓  AI feedback per answer ✓  Gap analysis per quiz ✓  ~6 min per quiz
Explore All Quizzes  ↗

Materials failing at sign-off costs more than time

Every failed review cycle means delayed launches, frustrated teams, and mounting risk. Most pharmaceutical companies don't have a shortage of good content — they have a shortage of consistent, confident compliance judgement.

That's where I come in. With 26 years of pharmaceutical leadership — including roles as a GMC-registered physician, ABPI Final Medical Signatory, and FFPM — I help teams build the knowledge and processes to get it right first time.

GMC Registered Pharmaceutical Physician
ABPI Qualified Person (Final Signatory)
Fellow of the Faculty of Pharmaceutical Medicine (FFPM)
MBA — London Business School
1,900+ PMCPA cases personally reviewed
About Anzal
Dr Anzal Qurbain

End-to-end ABPI compliance support

From one-off signatory cover to full team transformation — choose the support that fits your situation.

Get instant ABPI compliance answers — 24/7

AskAnzal AI gives pharmaceutical professionals instant access to 13 specialist compliance advisors, each trained on the ABPI Code 2024, MHRA guidance, EFPIA, and IPHA.

  • ✓ 13 specialist advisors covering every clause of the ABPI Code
  • ✓ Powered by the ABPI Code 2024, MHRA Blue Guide, EFPIA & IPHA
  • ✓ Get answers in seconds, not days
  • ✓ Available 24/7 — no waiting for a sign-off meeting
  • ✓ From £19/month
AskAnzal AI — ABPI Advisor
Can I post about our new medicine on LinkedIn?
Anzal: Under Clause 16 of the ABPI Code 2024, social media posts about prescription medicines must not promote to the public. LinkedIn reaches a mixed audience — you would need to implement adequate audience controls or restrict the content to verified HCPs only...
What audience controls are acceptable?

Latest PMCPA Case Analysis

Real rulings. Practical lessons. Published every day.

View All 1,900+ Cases ↗
08
Mar
Takeda v Amdipharm Mercury

Takeda v Amdipharm Mercury: Lutrate email implied interchangeability with Prostap and overstated cost savings

08
Mar
AUTH/2873/9/16

Actelion ruled in breach for offering frozen yoghurt at an exhibition stand (AUTH/2873/9/16)

08
Mar
AUTH/2845/5/16

AUTH/2845/5/16: CSL Behring v Swedish Orphan Biovitrum (Sobi) — Charity ball (No breach)

08
Mar
AUTH/2892/11/16

AUTH/2892/11/16: Anonymous (non-contactable) v Galen — Trustsaver website savings claims (No breach)

08
Mar
AUTH/2864/8/16

AUTH/2864/8/16: Anonymous (non-contactable) v Boehringer Ingelheim – consultant engagement, training workshops and alleged audit-linked switching (No breach)

ABPI Compliance Thinking

In-depth analysis of the issues that matter to compliance leads.

All Insights ↗

What clients say

★★★★★

"Anzal's mentorship programme completely changed how our team approaches materials review. We went from 4-5 review cycles to 1-2. The ROI was immediate."

Medical Affairs Director
Global Pharmaceutical Company
★★★★★

"The workshop was unlike anything we'd done before — Anzal used our own materials and showed us exactly where the risks were. Incredibly practical and immediately applicable."

Head of Regulatory Affairs
UK Pharma Company
★★★★★

"Having Anzal as our on-demand signatory gave us the capacity we needed during a critical launch period. Fast, thorough, and always commercially aware."

VP Medical & Regulatory
Specialty Pharma

Ready to get your materials approved faster?

Book a free 30-minute call to discuss your team's compliance challenges. No obligation — just straight answers from someone who's been on both sides of the sign-off table.

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free